NEUROMOD RESULTS: “Reproducible and Long-Term Efficacy of a New Treatment for Tinnitus”

Neuromod Device study results accidentally posted online or just very hard to find?

This information was discovered within a .pdf document hosted on the American Auditory Society website. The 19-page document is a collection of podium abstracts for the upcoming American Auditory Society Scientific and Technology Meeting (February 28 – March 2, 2019). And one of these abstracts is for the long-awaited Neuromod Device study results.

Interestingly, the web address where this information was found is “public” and indexed by Google (see screenshot). However, for some reason it is post-dated March 2, 2019. Was this abstract supposed to be public so soon?

Neuromod Device study results abstract… from the future?

Neuromod Device study results (podium abstract) from upcoming AAS meeting

Reproducible and Long-Term Efficacy of a New Treatment for Tinnitus

Tinnitus affects ~10-15% of the population. Unfortunately, there are limited treatment options. A new non-invasive neuromodulation device using auditory (sound) and trigeminal nerve (tongue) stimulation has been evaluated in more than 500 tinnitus patients across two randomized and blinded clinical trials. The first study explored the effects of three MBT stimulation settings (PS1, PS2, PS3) that were presented for 12 weeks (~30-60 minutes per day) and evaluated during treatment and up to 12 months posttreatment (326 enrolled patients). Pre-specified primary outcome measures included the Tinnitus Handicap Inventory (THI) and Tinnitus Functional Index (TFI). All three MBT settings resulted in statistically and clinically significant improvements in tinnitus during treatment. Post-treatment, PS1 resulted in long-term improvements lasting 12 months that clinically outperformed the other stimulation settings. The treatment was safe and well-tolerated with a high compliance rate (84%). Encouragingly, the greatest therapeutic effects were observed within the first 6 weeks of treatment, which was repeatable for PS1 in an ongoing second clinical trial in 191 patients. These two clinical trials represent one of the largest clinical trial datasets for tinnitus treatments, demonstrating safe, fast-acting (within 6 weeks) and reproducible therapeutic effects that can last at least 12 months with appropriate stimulation settings.

SOURCE:
https://aas.memberclicks.net/assets/19_Podiums.pdf


Subscribe to Email Updates

Newsletter subscribers get early access to our latest articles. Expect 1 to 3 emails per week.

This field is for validation purposes and should be left unchanged.

No spam, no third parties, and 100% free. Your information is kept private. Unsubscribe with one click anytime.